Pharmaceuticals (Jan 2024)

Alpha-Emitting Radionuclides: Current Status and Future Perspectives

  • Matthias Miederer,
  • Martina Benešová-Schäfer,
  • Constantin Mamat,
  • David Kästner,
  • Marc Pretze,
  • Enrico Michler,
  • Claudia Brogsitter,
  • Jörg Kotzerke,
  • Klaus Kopka,
  • David A. Scheinberg,
  • Michael R. McDevitt

DOI
https://doi.org/10.3390/ph17010076
Journal volume & issue
Vol. 17, no. 1
p. 76

Abstract

Read online

The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.

Keywords